FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients
U.S. Food and Drug Administration
Individuals who received two mg or three mg of Rexulti showed statistically significant and clinically meaningful improvements
Individuals who received two mg or three mg of Rexulti showed statistically significant and clinically meaningful improvements